Over the past decade, increased survival times have been tied to the emergence of targeted and checkpoint blockade therapies as the standard of care for most patients with metastatic non-small cell lung cancer (NSCLC). Given advancements in this setting, investigators have been exploring ways to bring these life-saving treatments to more patients with lung cancer across additional settings. "In terms of the changes, the [breakthroughs] that have happened over the past 5 years are indicative of how quickly we're moving in the field," Benjamin Levy, MD, a thoracic medical oncologist and clinical director of medical oncology at Johns Hopkins Sidney Kimmel Cancer Center in Washington, DC, said in an interview. "When I started, a lot of the talks were just on chemotherapy and potentially immunotherapy, and now we've got such a huge charge to cover all the new approvals for all the new drugs."
展开▼
